You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Immunotoxins

Showing 1 - 25 of 61
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hairy Cell and Other Leukemias, and to Develop Recombinant

Recruiting
  • Hairy Cell Leukemia (HCL)
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Aug 24, 2022

    Leukemia Trial in Bronx (deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins)

    Completed
    • Leukemia
    • deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins
    • Bronx, New York
      Albert Einstein Cancer Center at Albert Einstein College of Medi
    Apr 9, 2021

    Pancreatic Cancer Trial in Shatin (MSLN CART)

    Not yet recruiting
    • Pancreatic Cancer
    • MSLN CART
    • Shatin, N.t., Hong Kong
      Endoscopy Centre, Prince of Wales Hospital
    Sep 19, 2023

    Adult B Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia Trial in Bronx, Philadelphia (drug,

    Terminated
    • Adult B Acute Lymphoblastic Leukemia
    • Recurrent Adult Acute Lymphoblastic Leukemia
    • Bronx, New York
    • +1 more
    Sep 4, 2019

    Adult T-Cell Leukemia (ATL) Trial run by the NCI (LMB-2, Fludarabine, Cyclophosphamide)

    Active, not recruiting
    Has Results
    • Adult T-Cell Leukemia (ATL)
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Jan 13, 2022

    Multiple Myeloma, Myeloma, Plasma-Cell, PLASMACYTOMA Trial in United States (milatuzumab)

    Completed
    • Multiple Myeloma
    • +2 more
    • milatuzumab
    • Atlanta, Georgia
    • +5 more
    Aug 12, 2021

    Malignant Non-Hodgkin Lymphomas Trial in Berne (CD34+ cell selection)

    Active, not recruiting
    • Malignant Non-Hodgkin Lymphomas
    • CD34+ cell selection
    • Berne, Switzerland
      Department for Medical Oncology; University Hospital/Inselspital
    Jul 29, 2021

    Acute Lymphoblastic Leukemia Treated With Anti-CD22

    Recruiting
    • Acute Lymphoblastic Leukemia
    • Anti-CD22 Immunotoxin
    • Meldola (FC), FC, Italy
    • +4 more
    Feb 25, 2021

    B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive,

    Completed
    • B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
    • +6 more
    • Houston, Texas
      M D Anderson Cancer Center
    Mar 25, 2022

    Hairy Cell Leukemia Trial run by the NCI (Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin)

    Active, not recruiting
    Has Results
    • Hairy Cell Leukemia
    • Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Apr 13, 2022

    GVHD, Immune System Disorders Trial in United States (Etanercept, Mycophenolate Mofetil, Denileukin Diftitox)

    Completed
    Has Results
    • Graft vs Host Disease
    • Immune System Disorders
    • Duarte, California
    • +18 more
    Oct 19, 2021

    Recurrent Osteosarcoma Trial in Canada, Puerto Rico, United States (Glembatumumab Vedotin, Laboratory Biomarker Analysis,

    Completed
    Has Results
    • Recurrent Osteosarcoma
    • Glembatumumab Vedotin
    • +2 more
    • Birmingham, Alabama
    • +154 more
    Jan 6, 2022

    Mesothelioma Trial run by the National Cancer Institute (NCI) (LMB-100, nab-paclitaxel)

    Completed
    Has Results
    • Mesothelioma
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jul 28, 2022

    Adult T Cell Leukemia, Adult T Cell Lymphoma Trial in Bronx (IMTOX-25)

    Completed
    • Adult T Cell Leukemia
    • Adult T Cell Lymphoma
    • Bronx, New York
    • +6 more
    Sep 4, 2019

    Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 Trial in United States (Glembatumumab Vedotin, Laboratory Biomarker

    Completed
    Has Results
    • Recurrent Uveal Melanoma
    • Stage IV Uveal Melanoma AJCC v7
    • Glembatumumab Vedotin
    • +2 more
    • Phoenix, Arizona
    • +24 more
    Jul 30, 2020

    Bladder Cancer, Breast Cancer, Colorectal Cancer Trial in Baltimore, Bethesda (LMB-9 immunotoxin)

    Completed
    • Bladder Cancer
    • +5 more
    • LMB-9 immunotoxin
    • Baltimore, Maryland
    • +1 more
    Oct 31, 2019

    CD19-positive ALL Trial in Zhengzhou (anti-CD19/CD22 CAR-T cells, Fludarabine, Cyclophosphamide)

    Unknown status
    • CD19-positive ALL
    • anti-CD19/CD22 CAR-T cells
    • +2 more
    • Zhengzhou, Henan, China
      Henan Province of TCM
    Mar 9, 2020

    Lymphoma Trial in Dallas (RFT5-dgA immunotoxin, fluorescence activated cell sorting, immunohistochemistry staining method)

    Terminated
    Has Results
    • Lymphoma
    • RFT5-dgA immunotoxin
    • +2 more
    • Dallas, Texas
      Simmons Comprehensive Cancer Center at University of Texas South
    Nov 21, 2018

    Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma Trial in Seattle (biological,

    Completed
    • Fallopian Tube Cancer
    • +10 more
    • denileukin diftitox
    • +4 more
    • Seattle, Washington
      Fred Hutchinson Cancer Research Center/University of Washington
    May 13, 2019

    GVHD Trial in Münster, Nijmegen (T-Guard)

    Completed
    • Graft vs Host Disease
    • T-Guard
    • Münster, North Rhine-Westphalia, Germany
    • +1 more
    Jun 3, 2017

    Tumors, Pancreatic Tumors Trial run by the NCI (LMB-100, Nab-Paclitaxel, Mesothelin Expression)

    Completed
    Has Results
    • Neoplasms
    • Pancreatic Neoplasms
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 16, 2022

    Previously Collected and Stored Tissue Samples From Patients

    Terminated
    • Cancer
    • gene expression analysis
    • +6 more
    • (no location specified)
    Oct 4, 2018

    GVHD, Steroid Refractory GVHD, Acute GVH Disease Trial in Gainesville, Columbus, San Antonio (Infliximab and Basiliximab)

    Terminated
    Has Results
    • Graft Versus Host Disease
    • +2 more
    • Infliximab and Basiliximab
    • Gainesville, Florida
    • +2 more
    Apr 3, 2019

    Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer Trial in Seattle (biological, other, genetic)

    Completed
    Has Results
    • Male Breast Cancer
    • +5 more
    • ONTAK
    • +5 more
    • Seattle, Washington
      Fred Hutchinson Cancer Research Center/University of Washington
    Nov 9, 2018

    Advanced Malignant Solid Tumor, Estrogen Receptor Negative, GPNMB Positive Trial (drug, biological, other)

    Withdrawn
    • Advanced Malignant Solid Neoplasm
    • +17 more
    • Glembatumumab Vedotin
    • +4 more
    • (no location specified)
    Jul 17, 2018